Ignite Creation Date:
2025-12-26 @ 12:16 PM
Ignite Modification Date:
2026-03-04 @ 8:14 PM
Study NCT ID:
NCT02821000
Status:
COMPLETED
Last Update Posted:
2024-05-30
First Post:
2016-06-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-07-08
Start Date Type:
ACTUAL
Primary Completion Date:
2017-12-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-11-30
Completion Date Type:
ACTUAL
First Submit Date:
2016-06-29
First Submit QC Date:
None
Study First Post Date:
2016-07-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-12-10
Results First Submit QC Date:
None
Results First Post Date:
2019-03-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-18
Last Update Post Date:
2024-05-30
Last Update Post Date Type:
ACTUAL